Larimar Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $26.
Portfolio Pulse from Benzinga Newsdesk
Larimar Therapeutics shares rose after Oppenheimer initiated coverage with an Outperform rating and a $26 price target.
October 16, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer's initiation of coverage with an Outperform rating and a $26 price target has positively impacted Larimar Therapeutics' stock price.
The initiation of coverage by a reputable firm like Oppenheimer with a positive rating and a specific price target often leads to increased investor confidence and buying activity, driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100